Sandbox Reserved 425: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 51: | Line 51: | ||
==Quiz Question 1== | ==Quiz Question 1== | ||
Ponatinib is unique in it's ability to bind to the mutated BCR- | Ponatinib is unique in it's ability to bind to the mutated BCR-ABL because of it's preference to shift to the DFG-out conformation. In theory, if a competitive inhibitor was created by nature to prevent Ponatinib from binding to BCR-ABL to further its drug resistance, what specific structure characteristics would the inhibitor need to posses? Consider the unique binding methods of Ponatinib and the <scene name='48/483882/Active_sitezoom/1'>DFG-out</scene> conformation. | ||
a. | a. Small, fully conjugated aromatic system with no electronegative substituents, to prevent unwanted hydrogen bonding. | ||
b. | b. Multiple ring system, one ring, particularly for hydrogen bonding and another capable of binding in a hydrophobic pocket such as halogen substituents. | ||
c. | c. Polymer chain with an ester linkage and a hydroxyl end group . | ||
d. | d. Metal center that binds four large, nonpolar hydrocarbon ligands that exhibit significant steric hindrance. | ||
==See Also== | ==See Also== | ||